TG Therapeutics, Inc.

NasdaqCM:TGTX Stok Raporu

Piyasa değeri: US$3.9b

TG Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

TG Therapeutics has been growing earnings at an average annual rate of 21.1%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 91.6% per year. TG Therapeutics's return on equity is 53.9%, and it has net margins of 27.6%.

Anahtar bilgiler

21.1%

Kazanç büyüme oranı

28.0%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı91.6%
Özkaynak getirisi53.9%
Net Marj27.6%
Sonraki Kazanç Güncellemesi04 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry

Sep 01
TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 09
Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback

Aug 07

TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet

Aug 02
TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet

Hold TG Therapeutics For Intriguing Outcomes

Jun 12

TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement

May 29
TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement

TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 04
TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

TG Therapeutics: Less Room For Doubt About Briumvi

May 03

News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

May 03
News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

Mar 25
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

TG Therapeutics: Briumvi Growth Story Appears Intact

Mar 01

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 01
Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference

Jan 10

Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S

Jan 04
Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S

Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?

Nov 24
Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?

TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar

Sep 30
TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar

Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Aug 03
Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Jul 19
Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?

Apr 13
Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?

Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?

Jan 02
Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?

TG Therapeutics: Elucidating The Upcoming Binary

Oct 09

TG Therapeutics: We Are Just Hanging In There

Sep 21

Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt

Sep 07
Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt

TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials

Aug 25

TG Therapeutics Q2 2022 Earnings Preview

Aug 05

Gelir ve Gider Dağılımı

TG Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqCM:TGTX Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 243479613782
31 Mar 242894112993
31 Dec 232341312376
30 Sep 23190-2611488
30 Jun 2324-1769694
31 Mar 239-1697793
31 Dec 223-19870125
30 Sep 225-23980158
30 Jun 227-288101190
31 Mar 228-326122208
31 Dec 217-348128223
30 Sep 214-343140203
30 Jun 212-345140201
31 Mar 211-319120193
31 Dec 200-279108166
30 Sep 200-23171154
30 Jun 200-20639161
31 Mar 200-18927158
31 Dec 190-17315154
30 Sep 190-18710176
30 Jun 190-1598151
31 Mar 190-16711157
31 Dec 180-17315159
30 Sep 180-15018133
30 Jun 180-14822127
31 Mar 180-13218115
31 Dec 170-11816103
30 Sep 170-1111399
30 Jun 170-1051293
31 Mar 170-921280
31 Dec 160-781069
30 Sep 160-721162
30 Jun 160-611052
31 Mar 160-621350
31 Dec 150-631648
30 Sep 150-641748
30 Jun 150-681850
31 Mar 150-631845
31 Dec 140-561640
30 Sep 140-431429
30 Jun 140-301118
31 Mar 140-24817
31 Dec 130-20714

Kaliteli Kazançlar: TGTX has high quality earnings.

Büyüyen Kar Marjı: TGTX became profitable in the past.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: TGTX has become profitable over the past 5 years, growing earnings by 21.1% per year.

Büyüme Hızlandırma: TGTX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Kazançlar vs. Sektör: TGTX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Özkaynak Getirisi

Yüksek ROE: TGTX's Return on Equity (53.9%) is considered outstanding.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin